Investigational Drug Information for Pictilisib
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Pictilisib?
Pictilisib is an investigational drug.
There have been 6 clinical trials for Pictilisib.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 20th 2012.
The most common disease conditions in clinical trials are Breast Neoplasms, Gliosarcoma, and Glioblastoma. The leading clinical trial sponsors are Genentech, Inc., Roche Pharma AG, and Royal Marsden NHS Foundation Trust.
Summary for Pictilisib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,996 |
| WIPO Patent Applications | 1,398 |
| Japanese Patent Applications | 634 |
| Clinical Trial Progress | Phase 2 (2012-01-20) |
| Vendors | 96 |
Recent Clinical Trials for Pictilisib
| Title | Sponsor | Phase |
|---|---|---|
| PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib | Institute of Cancer Research, United Kingdom | Phase 1 |
| PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib | Pfizer | Phase 1 |
| PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib | Roche Pharma AG | Phase 1 |
Clinical Trial Summary for Pictilisib
Top disease conditions for Pictilisib
Top clinical trial sponsors for Pictilisib
US Patents for Pictilisib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
